XML 67 R57.htm IDEA: XBRL DOCUMENT
v3.21.2

License Funding and Other Agreements Related to the CVR - Additional Information (Details) - USD ($) $ in Millions |  |  | 1 Months Ended | 3 Months Ended | 6 Months Ended |
--- | --- | --- | --- | --- | --- | ---
Jul. 27, 2021 | Oct. 31, 2020 | Feb. 28, 2021 | Nov. 30, 2020 | May 31, 2019 | Jun. 30, 2021 | Jun. 30, 2021 | Mar. 23, 2017
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |
Exercised Investment Right and Purchased |  |  |  |  |  |  | $ 10.0 |
Estimated fair value of the CVR liability |  |  |  |  |  | $ 0.0 | 0.0 |
Funding Agreement |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |
Qualifying expenses |  |  |  |  |  |  | 0.3 |
National Institute of Health |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |
Grant term |  |  |  |  | 5 years |  |  |
Grants receivable |  |  |  |  | $ 1.5 |  |  |
Qualifying expenses |  |  |  |  |  | 0.3 |  |
Qualifying expenses on cumulative basis |  |  |  |  |  |  | 1.3 |
National Institute of Health | Funding Agreement |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |
Qualifying expenses |  |  |  |  |  | 0.1 | 0.5 |
Qualifying expenses on cumulative basis |  |  |  |  |  |  | 1.3 |
Contingent Value Rights Agreement | C O V I D19 |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |
Total fees and expenses related to clinical trials |  | $ 1.1 |  |  |  |  | 3.0 |
Post Exposure Prophylaxis in adults |  |  | In February 2021, management terminated the National Institute on Aging study of RTB101 for COVID-19 post-exposure prophylaxis in adults age 65 years and older due to poor enrollment |  |  |  |  |
Increase decrease in estimated fair value of CVR liability |  |  |  | $ 0.4 |  |  |  |
Estimated fair value of the CVR liability |  |  |  | $ 0.6 |  | $ 0.0 | $ 0.0 |
Novartis License Agreement | Novartis International Pharmaceutical Ltd. |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |
License agreement termination description | On, July 27, 2021, the Company sent Novartis a termination notice. Termination will automatically take effect as of 60 days from the date of delivery of the termination notice to Novartis, but in no event later than October 1, 2021 without any further notice or action required of either Novartis or the Company. |  |  |  |  |  | The agreement may be terminated by either party upon a material breach of obligation by the other party that is not cured with 60 days after written notice. resTORbio may terminate the agreement in its entirety or on a product-by-product or country-by-country basis with or without cause with 60 days’ prior written notice. |
Novartis License Agreement | Novartis International Pharmaceutical Ltd. | Maximum |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |
Aggregate amount payable upon satisfaction of clinical milestones |  |  |  |  |  |  |  | $ 4.3
Aggregate amount payable upon satisfaction of regulatory milestones for first indication approved |  |  |  |  |  |  |  | 24.0
Aggregate amount payable upon satisfaction of regulatory milestones for second indication approved |  |  |  |  |  |  |  | 18.0
Aggregate amount payable upon satisfaction of commercial milestones |  |  |  |  |  |  |  | $ 125.0

X
- Definition Estimated fair value of CVR liability. + References No definition available. + Details
Name: | acet_EstimatedFairValueOfCVRLiability
Namespace Prefix: | acet_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Exercised Investment Right and Purchased + References No definition available. + Details
Name: | acet_ExercisedInvestmentRightAndPurchased
Namespace Prefix: | acet_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Fees and expense incurred in connection with clinical trials. + References No definition available. + Details
Name: | acet_FeesAndExpenseIncurredInConnectionWithClinicalTrials
Namespace Prefix: | acet_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Grant term. + References No definition available. + Details
Name: | acet_GrantTerm
Namespace Prefix: | acet_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Increase decrease in estimated fair value of cvr liability. + References No definition available. + Details
Name: | acet_IncreaseDecreaseInEstimatedFairValueOfCvrLiability
Namespace Prefix: | acet_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition License agreement milestone payments upon satisfaction of clinical milestones payable. + References No definition available. + Details
Name: | acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfClinicalMilestonesPayable
Namespace Prefix: | acet_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition License agreement milestone payments upon satisfaction of commercial milestones payable. + References No definition available. + Details
Name: | acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfCommercialMilestonesPayable
Namespace Prefix: | acet_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition License agreement milestone payments upon satisfaction of regulatory milestones payable for first indication approved. + References No definition available. + Details
Name: | acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForFirstIndicationApproved
Namespace Prefix: | acet_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition License agreement milestone payments upon satisfaction of regulatory milestones payable for second indication approved. + References No definition available. + Details
Name: | acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForSecondIndicationApproved
Namespace Prefix: | acet_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition License agreement termination description. + References No definition available. + Details
Name: | acet_LicenseAgreementTerminationDescription
Namespace Prefix: | acet_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Post Exposure Prophylaxis in adults + References No definition available. + Details
Name: | acet_PostExposureProphylaxisDescription
Namespace Prefix: | acet_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Qualifying expenses. + References No definition available. + Details
Name: | acet_QualifyingExpenses
Namespace Prefix: | acet_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition qualifying expenses on cumulative basis. + References No definition available. + Details
Name: | acet_QualifyingExpensesOnCumulativeBasis
Namespace Prefix: | acet_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.8) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_GrantsReceivable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=acet_ResearchFundingAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acet_NationalInstitutesOfHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=acet_ContingentValueRightsAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_UnusualRiskOrUncertaintyByNatureAxis=acet_COVID19Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=acet_NovartisLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acet_NovartisInternationalPharmaceuticalLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |